KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior sys ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA ® (pembrolizumab), in combination with paclitaxel, with or without bevacizumab, is approved in the ...

BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when combined ...

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in China, Akeso and Summit Therapeutics’ ivonescimab has shown it can delay ...